Trial
NCT04204252
Phase III, Efficacy and Safety of "Kamada-AAT for Inhalation"
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Kamada, Ltd.
Collaborators
Syneos Health
Condition
Alpha 1-Antitrypsin Deficiency
Intervention
Alpha 1-Antitrypsin
Why stopped
Following interim analysis for futility
Provenance
Dataset: 2026-08-14 • Source: ClinicalTrials.gov API v2 • Last update: 2026-08-12